Hamburg based HELM AG has purchased a 30% shareholding in Amarin Technologies S.A. a privately owned pharmaceutical development company in Buenos Aires, Argentina.

Amarin has more than 20 years of experience in the technology of transdermal delivery systems and owns several patents. The mid-size company has been cooperating with HELM successfully on the development of a pain release patch.

Both Sergio Lucero, CEO of Amarin, and Dieter Schnabel, CEO of HELM, are convinced that HELM, with its marketing strength in more than 32 countries is a perfect fit for Amarin's expertise in transdermal technology. "We are confident that this strategic step will be very beneficial to both companies."

The participation gives HELM's pharmaceutical division direct access to various generic transdermal products, presently still a niche market but with strong growth potential. It will further strengthen the company's position within the global pharmaceutical market. At the same time, it increases Amarin's access to international markets.